Role of fibrates in reducing coronary risk: A UK Consensus

Current Medical Research and Opinion

Volumn 20, Issue 2, 2004, Pages 241-247

  Mikhailidis, D P ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Coronary heart disease; Diabetes; Fibrates; High density lipoprotein cholesterol; Metabolic syndrome; Statins

Indexed keywords

BEZAFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN;

CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; CORONARY RISK; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; EVIDENCE BASED MEDICINE; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; METABOLIC SYNDROME X; MYOPATHY; PRACTICE GUIDELINE; RISK BENEFIT ANALYSIS; UNITED KINGDOM;

ANTILIPEMIC AGENTS; BEZAFIBRATE; CHOLESTEROL, HDL; CORONARY DISEASE; DRUG THERAPY, COMBINATION; GEMFIBROZIL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; METABOLIC SYNDROME X; PROCETOFEN;

EID: 1042302811     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125002892     Document Type: Conference Paper

References (36)

1. Fruchart JC, Brewer HB Jr, Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. Am J Cardiol 1998;81:912-7
2. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaeffer EJ, Schectman G, Wilt TJ, Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-8
3. Manninen V, Elo O, Frick H, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P et al. Lipid alterations and decline in the incidence of coronary heart disease - the Helsinki Heart Study. JAMA 1988;260(5):641-51
4. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica W, Arnold JMO, Wun C-C, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;333:1001-9
5. Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57
6. MRC/BHF Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7-22
7. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998;80(Suppl 2):S1-S29
8. Expert panel in detection, evaluation and treatment of high blood cholesterol in adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
9. Sacks FM, for the Expert Group on HDL Cholesterol. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: Expert Group recommendations. Am J Cardiol 2002;90:139-43
10. Department of Health. National Service Framework for Coronary Heart Disease, London, 2000
11. Sacks FM. Clinical usefulness of HDL cholesterol as a target to lower risk or coronary heart disease. Brit J Cardiol 2003;10(4):297-304
12. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53
13. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-9
14. Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR, Holman RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS:23). BMJ 1998;316:823-8
15. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124:S11-S20
16. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR, Bangdiwala S, Tyroler A. High-density lipoprotein cholesterol and cardiovascular disease. Circulation 1989;79:8-15
17. Gordon DJ, Rifkind BM. High-density lipoprotein - the clinical implications of recent studies. New Engl J Med 1989;321(19):1311-6
18. Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin JS, Morris R, Zavaroni I, van Dam R, Feskins E, Gabriel R, Diet M, Nilsson P, Hedblad B. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002;28(5):364-76
19. Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM, Keech A, Packard C, Simes J, Byington R, Furberg CD. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project. Circulation 2000;102:1893-1900
20. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423
21. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58
22. Sacks FM. The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials. Am J Cardiol 2001;88(Suppl):14N-18N
23. WHO co-operative study on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators. Lancet 1984;2:600-4
24. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000;102:21-7
25. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992;85:37-45
26. Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety. Eur Heart J 1995;16(1):5-13
27. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001;35:908-17
28. Wierzbicki AS, Mikhailidis DP, Wray R, Schacter M, Cramb R, Simpson WG, Byrne CB. Statin-fibrate combination: therapy for hyperlipidemia: a review. Curr Med Res Opin 2003;19(3):155-68
29. Vega GL, Ma PTS, Carter NB, Filipchuk N, Meguro S, Garcia-Garcia AB, Grundy SM. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidaemia and metabolic syndrome. Am J Cardiol 2003;91:956-60
30. Telford M, Elisaf M. Clinical pharmacokinetics of fenofibrate. Curr Med Res Opin 2003;19:139-40
31. American Diabetes Association Clinical Practice Recommendations 2003. Diabetes Care 2003;26:S1-S156
32. Management of type 2 Diabetes. Clinical Guideline H. National Institute of Clinical Excellence, London, 2002
33. Tenkanen LJ, Manttari M, Manninen V. Some coronary risk factors related to insulin resistance syndrome and treatment with gemfibrozil. Evidence from the Helsinki Heart Study. Circulation 1995;92:1779-85
34. Poulter N. The impact of fenofibrate on lipid subfractions and on reaching HDL target levels in 7,098 patients with dyslipidaemia. Br J Cardiol 1999;6(12):682-5
35. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW. Diabetes, plasma insulin and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 2002;162:2597-604
36. Meade T, Zuhrie R, Cook C, Cooper J. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 2002;325(7373):1139-44